Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]
News [3529]
Articles [90]
Editorials [5]
Conferences [156]
elearning [19]
The 2022 OncoAlert Colloquium Day 3: Lung Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 3: Lung Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 2: GU Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 2: GU Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 1: Breast Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
30 Jan 2023
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...
Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2023
ASH 2022: Multiple myeloma roundup
Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...
Dr Mark Litzow - Mayo Clinic, Rochester, USA
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )
19 Dec 2022
Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...
Dr Sara Hurvitz - University of California, Los Angeles, USA
Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )
15 Dec 2022
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...
Dr Emma Searle - University of Manchester, Manchester, UK
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )
12 Dec 2022
Systemic anti-cancer performance matrix
Prof Richard Sullivan, Kari Leung and Megan McLeod
Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )
23 Nov 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation